hemab.comCrawled Nov 1, 2026
Hemab targets bleeding and clotting disorders, including Glanzmann thrombasthenia and Von Willebrand disease.
The page provides clinical trials, treatment guidelines, and professional resources for healthcare providers treating bleeding and thrombotic disorders.
Find contact information, educational materials, support resources and care guidelines designed specifically for patients and caregivers managing bleeding disorders.
Hemab shares its latest news, press releases, and media resources on bleeding disorder research.
The page details the first-in-human investigation of HMB-002, presented at ISTH 2026, alongside Hemab’s research updates.
The page examines how plasma overlay and timing affect antifibrinolytic assessment, based on ISTH 2026 research.
The page presents research on bleeding burden and prophylaxis use in Glanzmann thrombasthenia from ISTH 2026 and updates on Hemab’s work.
Read the full story on “ISTH 2026: Elevated Depression Prevalence and Psychological Burden Associated with Bleeding Frequency in GT” and stay informed on Hemab’s research updates, presentations and company announcements.
The page describes Hemab’s leadership, approach, and focus on developing new therapies for bleeding and thrombotic disorders.
Reach out to Hemab’s team for general inquiries, clinical trial information or medical affairs.
Hemab is pioneering the first preventative treatments and functional cures for patients with rare bleeding and thrombotic disorders.
The page outlines Hemab’s privacy rules and security measures for protecting personal information in clinical trials.
The page explains how Hemab collects, uses, and protects personal data on its website.
Expanded access, also called compassionate use, refers to the use of an investigational therapy outside of a clinical trial when the primary purpose is to diagnose, prevent or treat a serious or immediately life-threatening condition in a patient.
View the terms and conditions governing use of the Hemab website and related services.
